Q32 Bio (FRA:DB0) Buyback Yield %: -4.76 (As of Jul. 07, 2026)


FRA:DB0 Q32 Bio Inc FRA:DB0
17 GF Score
Price €11.33
! 6 Warning Signs
View Full Analysis

What is Q32 Bio Buyback Yield %?

Q32 Bio FRA:DB0 -0.18% 17 Buyback Yield % is -4.76 as of Jul. 07, 2026. GuruFocus rates FRA:DB0 with a GF Score™ of 17/100. The stock has 6 warning signs investors should review. Among 740 Biotechnology companies, Q32 Bio ranks better than 59.32% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Q32 Bio's current buyback yield was -4.76%.

Q32 Bio Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Q32 Bio's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q32 Bio Buyback Yield % Chart

Q32 Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
0.00 0.00 0.00 -108.88 0.00

Q32 Bio Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -11.03

FRA:DB0 vs CAMP, CDXS, KROS: Buyback Yield % Comparison

For the Biotechnology subindustry, Q32 Bio's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q32 Bio Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Q32 Bio's Buyback Yield % falls into.


FRA:DB0
17GF Score
Q32 Bio Inc FRA:DB0
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Q32 Bio Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Q32 Bio's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 33.68796
=0.00%

Q32 Bio's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 8.961) / 78.26515
=-11.45%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -4.76 mean?
Q32 Bio (FRA:DB0) has a Buyback Yield % of -4.76 as of Jul. 07, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Q32 Bio and its competitors. According to the industry distribution chart, Q32 Bio ranks #301 out of 740 companies in the Biotechnology industry, placing it in the top 40.7%.
Is Q32 Bio's Buyback Yield % too high?
Q32 Bio's current Buyback Yield % is -4.76. Based on the distribution chart, Q32 Bio ranks #301 out of 740 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Q32 Bio has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Q32 Bio's Buyback Yield % compare to CAMP and CDXS?
According to the Biotechnology industry distribution chart, Q32 Bio ranks #301 out of 740 companies for Buyback Yield %. This puts Q32 Bio in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Q32 Bio and its competitors. Q32 Bio's current Buyback Yield % is -4.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q32 Bio stock overvalued right now?
Q32 Bio (FRA:DB0) has a current Buyback Yield % of -4.76. The current Buyback Yield % is -4.76. Q32 Bio's overall GF Score™ is 17/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Q32 Bio (FRA:DB0), the current Buyback Yield % is -4.76 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Q32 Bio Business Description

Other Exchanges QTTB:USA
Address 830 Winter Street, Waltham, MA, USA, 02451
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
17GF Score

Get the complete analysis for FRA:DB0

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.33
Price